跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
优赫得 - NMPA Drug Approval Details
Approvals
/
NMPA
/
Trastuzumab Deruxtecan for Injection
Approved
生物制品
Trastuzumab Deruxtecan for Injection
Daiichi Sankyo Europe GmbH
🇨🇳 National Medical Products Administration
Approval Date
Mar 24, 2023
Approval ID
50e6036b0fd41a07
Company
Daiichi Sankyo Europe GmbH
Type
生物制品
Approval Details
Approval Id
50e6036b0fd41a07
Approval Number
国药准字SJ20230005
Generic Name
注射用德曲妥珠单抗
Generic Name En
Trastuzumab Deruxtecan for Injection
Trade Name
优赫得
Drug Type
生物制品
Dosage Form
注射剂
Strength
100mg/瓶
Reg Date
2023-03-24
Expired Date
2028-02-20
Company Name
Daiichi Sankyo Europe GmbH
Production Company Name
Baxter Oncology GmbH
Company Detail Path
/organization/daiichi-sankyo-europe-gmbh
Production Company Detail Path
/organization/baxter-oncology-gmbh
Approved
Quick Info
Agency
NMPA
Country
🇨🇳
Approval Date
Mar 24, 2023
Approval ID
50e6036b0fd41a07
Type
生物制品
Back to NMPA Approvals